Detalhe da pesquisa
1.
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Br J Haematol
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504454
2.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood
; 138(2): 113-121, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827114
3.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Blood
; 137(25): 3495-3506, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598678
4.
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031755
5.
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Haematologica
; 107(12): 2897-2904, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638548
6.
A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
Haematologica
; 106(11): 2940-2946, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33179472
7.
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Ann Hematol
; 100(4): 987-993, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495922
8.
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
Blood
; 131(22): 2449-2453, 2018 05 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29559480
9.
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 20(2): 202-215, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658935
10.
Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma.
Int J Cancer
; 144(4): 886-896, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30155929
11.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
; 391(10121): 659-667, 2018 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241979
12.
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Haematologica
; 104(1): 138-146, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171024
13.
Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma.
Eur J Haematol
; 103(1): 35-42, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985955
14.
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Am J Hematol
; 2018 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29884994
15.
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Br J Haematol
; 176(1): 37-49, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27858991
16.
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Br J Haematol
; 179(3): 439-448, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28770576
17.
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Haematologica
; 102(4): 746-754, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28126961
18.
Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association.
Haematologica
; 102(1): 150-159, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27758822
19.
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Hematol Oncol
; 35(4): 671-678, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27878835
20.
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Br J Haematol
; 173(5): 722-30, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27010483